FDA approves multi-dose tirzepatide vials for Mounjaro and Zepbound

The FDA approved a multiple-dose, single-patient-use vial for both Mounjaro and Zepbound (tirzepatide) on January 7, 2026, adding a vial-and-syringe option alongside the single-dose pens and single-dose vials already on the market. The approvals cover supplements S-041 for Mounjaro (NDA 215866) and S-037 for Zepbound (NDA 217806), both signed by John Sharretts, MD, director of the Division of Diabetes, Lipid Disorders, and Obesity in the FDA's Center for Drug Evaluation and Research ^[1][2].

Eli Lilly and Company submitted both applications on July 31, 2025 ^[1][2]. The letters say each supplement revises the prescribing information and medication guide and adds new carton and container labeling plus a set of Instructions for Use written specifically for the multi-dose vial ^[1][2].

Zepbound's current labeling lists the multi-dose vial in six strengths: 10 mg/2.4 mL for four 2.5 mg/0.6 mL doses, 20 mg/2.4 mL for four 5 mg/0.6 mL doses, 30 mg/2.4 mL for four 7.5 mg/0.6 mL doses, 40 mg/2.4 mL for four 10 mg/0.6 mL doses, 50 mg/2.4 mL for four 12.5 mg/0.6 mL doses, and 60 mg/2.4 mL for four 15 mg/0.6 mL doses ^[3]. Each vial holds 2.4 mL, enough for four weekly 0.6 mL doses ^[3]. The dosing instructions remain the same as for the other presentations: a starting dosage of 2.5 mg once weekly, with maintenance dosages of 5 mg, 10 mg or 15 mg for weight reduction and long-term maintenance ^[3].

The Mounjaro approval letter describes the same new presentation — a multiple-dose single-patient-use vial — but does not list strengths or fill volume in the letter text, so it has not been established from the approval letters whether the Mounjaro vial matches the Zepbound strengths exactly ^[2]. Both letters describe the product as "single-patient use," meaning the vial is not intended to be shared between people ^[1][2].

The approval changes how the drug is packaged, not what the drug does. Zepbound's labeling still carries a boxed warning that tirzepatide causes thyroid C-cell tumors in rats and states that it is unknown whether the drug causes those tumors, including medullary thyroid carcinoma, in humans; the drug is contraindicated in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2 ^[3]. Other labeled warnings include severe gastrointestinal reactions, acute kidney injury from volume depletion, gallbladder disease, pancreatitis, hypoglycemia when used with insulin or an insulin secretagogue, and pulmonary aspiration during general anesthesia or deep sedation ^[3]. The labeling also advises people using oral contraceptives to switch to a non-oral method or add a barrier method for four weeks after starting and after each dose increase ^[3].

Why it matters for patients

Tirzepatide has been sold as a single-dose pen and a single-dose vial; the multi-dose vial is a fourth format, and it changes the supplies a patient handles — a vial and syringes rather than a prefilled pen ^[1][2][3]. Because the vial is labeled single-patient use, it is not a product to split or share, even among household members ^[1][2].

The two approval letters do not state a price, a launch date, or whether the vial will cost more or less than the pens, so those questions have not been answered. It also has not been reported whether insurers or pharmacy benefit managers will cover the vial differently from other presentations.

What happens next

Within 14 days of the January 7 letters, Lilly must submit the updated labeling content in structured product labeling format so it appears in public labeling repositories ^[1][2]. Final printed carton and container labeling is due no more than 30 days after it is printed, and FDA approval is not required before that labeling is used ^[1][2]. Patent information tied to the change must be filed with the FDA on Form FDA 3542 within 30 days of approval for the listing to be timely ^[1][2].

A later Mounjaro approval letter, dated August 27, 2026, refers to the multi-dose vial Instructions for Use as the "version previously approved January 7, 2026," confirming that date as the version on file ^[4]. Neither letter states when the vials will reach pharmacies ^[1][2].